We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Strengthens Phase IV Clinical Trial Reporting Requirements
EMA Strengthens Phase IV Clinical Trial Reporting Requirements
Sponsors need to report new safety and efficacy findings that emerge during postmarket clinical trials in periodic safety update reports, or PSURs, submitted to the European Medicines Agency.